Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00299-6/fulltext?dgcid=hubspot_email_conferencealerts_bts24&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz--taaFVYiEwiWjRi3XYAvSSBgC1qeSQw_JUAY3QeOFoP-jLTCMEnNvxNKM4ff6h61dHvyNzjV2VQSSOeLQJMA85emeY4Q&_hsmi=335902023&utm_content=335902023&utm_source=hs_email